GCS 100

Drug Profile

GCS 100

Alternative Names: GBC-590; GCS-100; GCS-100LE; LJPC-101; NCCG

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Barbara Ann Karmanos Cancer Institute; Wayne State University
  • Developer GlycoGenesys; La Jolla Pharmaceutical Company; Prospect Therapeutics
  • Class Antineoplastics; Polysaccharides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell adhesion molecule inhibitors; Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Liver disorders; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal failure

Most Recent Events

  • 01 Jun 2016 La Jolla Pharmaceutical completes the phase II GCS-100-CS-4003 extension trial for Renal failure (chronic kidney disease) in USA (NCT02155673)
  • 15 Mar 2016 Biomarkers information updated
  • 08 May 2015 GCS 100 is available for licensing as of 08 May 2015. www.ljpc.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top